Meeting
2024 ASCO Annual Meeting
Development of clinically accessible nomograms to predict risk of brain metastases at baseline and follow-up in patients with non-small cell lung cancer.
Authors
Alireza Mansouri
Penn State College of Medicine, Hershey, PA
Alireza Mansouri , Hannah E. Wilding , Nicholas Mikolajewicz , Debarati Bhanja , Camille Moeckel , Ahmad Ozair , Nima Hamidi , Cyril Tankam , Mason Stoltzfus , Angel Ray Baroz , Caleb Stahl , Mara Trifoi , Cain Dudek , Manmeet Singh Ahluwalia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Brain Metastases
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 2035)
DOI
10.1200/JCO.2024.42.16_suppl.2035
Abstract #
2035
Poster Bd #
334
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A nation-wide genomic screening project for further development of targeted therapies in treatment-refractory non–small-cell lung cancer (LC-SCRUM-TRY).
First Author: Hiroki Izumi
Poster
2023 ASCO Annual Meeting
Contemporary biomarker testing rates in both early and advanced NSCLC: Results from the MYLUNG pragmatic study.
First Author: Makenzi Colleen Evangelist
Poster
2023 ASCO Annual Meeting
A master screening study to determine biomarker status and trial eligibility for patients with malignant tumors.
First Author: Benjamin J. Solomon
Poster
2021 ASCO Quality Care Symposium
Biomarker testing patterns and actionability in advanced non-small cell lung cancer (aNSCLC) at OneOncology (OneOnc).
First Author: Ari M. Vanderwalde